These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 31276980)

  • 1. The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy.
    Salati M; Caputo F; Cunningham D; Marcheselli L; Spallanzani A; Rimini M; Gelsomino F; Reggiani-Bonetti L; Andrikou K; Rovinelli F; Smyth E; Baratelli C; Kouvelakis K; Kalaitzaki R; Gillbanks A; Michalarea V; Cascinu S; Braconi C
    Eur J Cancer; 2019 Aug; 117():84-90. PubMed ID: 31276980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies.
    Grenader T; Nash S; Plotkin Y; Furuse J; Mizuno N; Okusaka T; Wasan H; Valle J; Bridgewater J
    Ann Oncol; 2015 Sep; 26(9):1910-1916. PubMed ID: 26037798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: a real-world experience.
    Wu CE; Chou WC; Hsieh CH; Chang JW; Lin CY; Yeh CN; Chen JS
    BMC Cancer; 2020 May; 20(1):422. PubMed ID: 32410631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator.
    Chen L; Chen Y; Zhang L; Xue Y; Zhang S; Li X; Song H
    Pathol Oncol Res; 2021; 27():1609811. PubMed ID: 34712105
    [No Abstract]   [Full Text] [Related]  

  • 5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy.
    Suzuki Y; Kan M; Kimura G; Umemoto K; Watanabe K; Sasaki M; Takahashi H; Hashimoto Y; Imaoka H; Ohno I; Mitsunaga S; Ikeda M
    J Gastroenterol; 2019 Mar; 54(3):281-290. PubMed ID: 30298469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.
    Cho KM; Park H; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
    Oncotarget; 2017 Jan; 8(2):2329-2341. PubMed ID: 27911876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease.
    Lamarca A; Benafif S; Ross P; Bridgewater J; Valle JW
    Eur J Cancer; 2015 Sep; 51(13):1694-703. PubMed ID: 26066735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy.
    Filippi R; Montagnani F; Lombardi P; Fornaro L; Aprile G; Casadei-Gardini A; Faloppi L; Palloni A; Satolli MA; Scartozzi M; Citarella F; Lutrino SE; Vivaldi C; Silvestris N; Rovesti G; Rimini M; Aglietta M; Brandi G; Leone F
    Acta Oncol; 2021 Oct; 60(10):1317-1324. PubMed ID: 34282710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy.
    Jin H; Zhang G; Liu X; Liu X; Chen C; Yu H; Huang X; Zhang Q; Yu J
    World J Surg Oncol; 2013 May; 11():112. PubMed ID: 23705622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era.
    Sun F; Zhu J; Lu S; Zhen Z; Wang J; Huang J; Ding Z; Zeng M; Sun X
    BMC Cancer; 2018 Jan; 18(1):5. PubMed ID: 29291712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer.
    McNamara MG; Templeton AJ; Maganti M; Walter T; Horgan AM; McKeever L; Min T; Amir E; Knox JJ
    Eur J Cancer; 2014 Jun; 50(9):1581-9. PubMed ID: 24630393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes.
    Lowery MA; Goff LW; Keenan BP; Jordan E; Wang R; Bocobo AG; Chou JF; O'Reilly EM; Harding JJ; Kemeny N; Capanu M; Griffin AC; McGuire J; Venook AP; Abou-Alfa GK; Kelley RK
    Cancer; 2019 Dec; 125(24):4426-4434. PubMed ID: 31454426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil count and the inflammation-based glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy.
    Li QQ; Lu ZH; Yang L; Lu M; Zhang XT; Li J; Zhou J; Wang XC; Gong JF; Gao J; Li J; Li Y; Shen L
    Asian Pac J Cancer Prev; 2014; 15(2):945-50. PubMed ID: 24568523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of pre-treatment Naples prognostic score (NPS) in patients with osteosarcoma.
    Yang Q; Chen T; Yao Z; Zhang X
    World J Surg Oncol; 2020 Jan; 18(1):24. PubMed ID: 32000789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials.
    Lamarca A; Ross P; Wasan HS; Hubner RA; McNamara MG; Lopes A; Manoharan P; Palmer D; Bridgewater J; Valle JW
    J Natl Cancer Inst; 2020 Feb; 112(2):200-210. PubMed ID: 31077311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome and patterns of care in advanced biliary tract carcinoma (ABC): experience from two tertiary institutions in the United Kingdom.
    Huggett MT; Passant H; Hurt C; Pereira SP; Bridgewater J; Mukherjee S
    Tumori; 2014; 100(2):219-24. PubMed ID: 24852869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemoglobin and Neutrophil Count as Prognostic Factors in Cholangiocarcinoma Patients in 2nd Line Treatment Setting: Results from a Small Monocentric Retrospective Study.
    Liguori C; Copparoni C; Felicetti C; Pecci F; Lupi A; Pinterpe G; Berardi R; Giampieri R
    Curr Oncol; 2023 Jan; 30(1):1032-1045. PubMed ID: 36661728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations.
    Neuzillet C; Casadei Gardini A; Brieau B; Vivaldi C; Smolenschi C; Brandi G; Tougeron D; Filippi R; Vienot A; Silvestris N; Pointet AL; Lonardi S; Rousseau B; Scartozzi M; Dahan L; Aprile G; Boussaha T; Malka D; Crusz SM; Le Sourd S; Meurisse A; Lièvre A; Vernerey D; ; ; ;
    Eur J Cancer; 2019 Apr; 111():94-106. PubMed ID: 30826661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study.
    Salati M; Rizzo A; Merz V; Messina C; Francesco C; Gelsomino F; Spallanzani A; Ricci AD; Palloni A; Frega G; De Lorenzo S; Carotenuto P; Pettorelli E; Benatti S; Luppi G; Melisi D; Brandi G; Dominici M
    Expert Rev Gastroenterol Hepatol; 2022 Jan; 16(1):73-79. PubMed ID: 34890512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index.
    Rovesti G; Leone F; Brandi G; Fornaro L; Scartozzi M; Niger M; Yoo C; Caputo F; Filippi R; Casagrande M; Silvestris N; Santini D; Faloppi L; Palloni A; Aglietta M; Vivaldi C; Cho H; Lai E; Fenocchio E; Nichetti F; Pella N; De Lorenzo S; Di Maio M; Vasile E; de Braud F; Jeong JH; Aprile G; Orsi G; Cascinu S; Casadei-Gardini A
    J Gastrointest Cancer; 2022 Jun; 53(2):289-298. PubMed ID: 33544375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.